Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R/R cHL patients. Methods Transplant-e...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-03-01
Serija:	BMC Medicine
Teme:	Hodgkin disease Camrelizumab Gemcitabine Oxaliplatin
Online dostop:	https://doi.org/10.1186/s12916-024-03329-8
Oznake:	Označite Brez oznak, prvi označite!